Cyclerion Therapeutics, Inc. (CYCN)

NCM – Real Time Price. Currency in USD

3.18

-0.01 (-0.31%)

At close: May 12, 2026, 4:00 PM EDT

3.18

0.00 (0.00%)

Pre-market: May 13, 2026, 4:00 AM EDT

02.04.2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

NEW YORK, April 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) related to its merger with Korsana Biosciences, Inc. Upon the closing of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company.

02.04.2026

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. Upon closing of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company. Halper Sadeh encourages Cyclerion shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@h.

01.04.2026

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, April 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Korsana. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

01.04.2026

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Under the deal, the combined company is expected to operate as Korsana Biosciences and trade on the Nasdaq under the ticker symbol KRSA. The move appears to be driving enthusiasm because it gives public-market investors exposure to Korsana's lead program, KRSA-028, a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease.

01.04.2026

Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

01.04.2026

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

WALTHAM, Mass.--(BUSINESS WIRE)---- $CYCN--Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the transaction, the combined company plans to operate under the name Korsana Biosciences, Inc. and trade on.

17.02.2026

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development – –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept (“POC”) Study in Treatment Resistant Depression (“TRD”) in the Second Half of 2026 – CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) (“Cyclerion” or "Company”), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126's Phase 2 POC study in TRD and its path to potential regulatory approval.

Videos

No Data

There is no data to display

Press releases

02.04.2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

02.04.2026

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

01.04.2026

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

01.04.2026

Cyclerion Therapeutics, Inc. (CYCN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cyclerion Therapeutics, Inc. (CYCN)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Videos

No Data

Press releases

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Videos

No Data

Press releases

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Search stocks

Cyclerion Therapeutics, Inc. (CYCN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cyclerion Therapeutics, Inc. (CYCN)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Videos

No Data

Press releases

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Videos

No Data

Press releases

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement